Ceftazidime Combined with a Short or Long Course of Amikacin for Empirical Therapy of Gram-Negative Bacteremia in Cancer Patients with Granulocytopenia

New England Journal of Medicine

Volumn 317, Issue 27, 1987, Pages 1692-1698

  Calandra, Thierry ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZLOCILLIN; CEFTAZIDIME;

BACTEREMIA; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG THERAPY; ESCHERICHIA COLI; GRANULOCYTOPENIA; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGRANULOCYTOSIS; AMIKACIN; AZLOCILLIN; CEFTAZIDIME; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; COMPARATIVE STUDY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIA; HUMAN; LEUKEMIA; LEUKOCYTE COUNT; MALE; MIDDLE AGE; NEOPLASMS; PROGNOSIS; RANDOM ALLOCATION; REGRESSION ANALYSIS; SEPTICEMIA; SUPPORT, NON-U.S. GOV'T;

EID: 0023551772     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198712313172703     Document Type: Article

References (32)

1. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284: 1061–5.
2. Pizzo PA. Empiric therapy and prevention of infection in the immunocompromised host. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 2nd ed. New York: John Wiley, 1985:1680–8.
3. The EORTC International Antimicrobial Therapy Project Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978; 137: 14–29.
4. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer. Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. J Clin Oncol 1983; 1: 597–603.
5. Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H. European Organization for Research on Treatment of Cancer Antimicrobial Therapy Project Group. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986; 29: 263–70.
6. Greene WH, Schimpff SC, Young VM, Wiernik PH. Empiric carbenicillin, gentamicin and cephalothin therapy for presumed infection in patients with granulocytopenia and cancer. Ann Intern Med 1973; 78: 825–6. abstract.
7. Gurwith M, Brunton JL, Lank B, Ronald AR, Harding GKM, McCullough DW. Granulocytopenia in hospitalized patients. II. A prospective comparison of two antibiotic regimens in the empiric therapy of febrile patients. Am J Med 1978; 64: 127–32.
8. Keating MJ, Bodey GP, Valdivieso M, Rodriguez V. A randomized comparative trial of three aminoglycosides — comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine (Baltimore) 1979; 58: 159–70.
9. Love LJ, Schimpff SC, Hahn DM, et al. Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer. Am J Med 1979; 66: 603–10.
10. Wade JC, Schimpff SC, Newman KA, Fortner CL, Standiford HC, Wiernik PH. Piperacillin or ticarcillin plus amikacin: a double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 1981; 71: 983–90.
11. Winston DJ, Ho WG, Young LS, Hewitt WL, Gale RP. Piperacillin plus amikacin therapy v. carbenicillin plus amikacin therapy in febrile, granulocytopenic patients. Arch Intern Med 1982; 142: 1663–7.
12. de Jongh CA, Wade JC, Schimpff SC, et al. Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin. Am J Med 1982; 73: 89–96.
13. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67: 608–16.
14. Winston DJ, Barnes RC, Ho WG, Young LS, Champlin RE, Gale RP. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med 1984; 77: 442–50.
15. Feld R, Louie TJ, Mandell L, et al. A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients. Arch Intern Med 1985; 145: 1083–8.
16. Klastersky J, Cappel R, Daneau D. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother 1972; 2: 470–5.
17. Klastersky J, Meunier-Carpentier F, Prevost J-M. Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am J Med Sci 1977; 273: 157–67.
18. Anderson ET, Young LS, Hewitt WL. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 1978; 24: 45–54.
19. Sculier JP, Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med 1984; 76: 429–35.
20. de Jongh CA, Joshi JH, Newman KA, et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986; 80: Suppl 5C: 96–100.
21. Love LJ, Schimpff SC, Schiffer CA, Wiernik PH. Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am J Med 1980; 68: 643–8.
22. Gribble MJ, Chow AW, Naiman SC, et al. Prospective randomized trial of piperacillin monotherapy versus earboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother 1983; 24: 388–93.
23. Young LS. Double β-lactam therapy in the immunocompromised host. J Antimicrob Chemother 1985; 16: 4–6.
24. Kramer BS, Ramphal R, Rand KH. Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother 1986; 30: 64–8.
25. de Pauw BE, Kauw F, Muytjens H, Williams KJ, Bothof T. Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother 1983; 12: Suppl A: 93–9.
26. Fainstein V, Bodey GP, Elting L, et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother 1983; 12: Suppl A: 101–10.
27. Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother 1984; 26: 870–5.
28. de Pauw B, Williams K, de Neeff J, et al. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1985; 28: 824–8.
29. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–8.
30. Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer clinical trials: methods and practice. Oxford: Oxford University Press, 1984.
31. Kramer BS, Ramphal R, Rand K. Antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1987; 316: 410–1.
32. Young LS. Empirical antimicrobial therapy in the neutropenic host. N Engl J Med 1986; 315: 580–1.